Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Celcuity Inc
(NQ:
CELC
)
17.45
+0.10 (+0.58%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Celcuity Inc
< Previous
1
2
3
4
Next >
Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences
April 05, 2022
MINNEAPOLIS, MN / ACCESSWIRE / April 5, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...
From
Celcuity Inc.
Via
AccessWire
Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates
March 23, 2022
- Finalized pivotal Phase 3 trial design following formal meetings with FDA - Received FDA Fast Track designation for gedatolisib in HR+/HER2- metastatic breast cancer - Presented updated Phase 1b data...
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
March 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Preview: Celcuity's Earnings
March 22, 2022
Celcuity (NASDAQ:CELC) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement. Analysts estimate...
Via
Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Exposures
Product Safety
Stocks That Hit 52-Week Lows On Thursday
March 24, 2022
On Thursday, 112 stocks made new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: Stanley Black & Decker (NYSE:SWK) was the largest firm by market...
Via
Benzinga
Celcuity Plans To Start Pivotal Gedatolisib Trial In Breast Cancer In 1H 2022
March 24, 2022
Via
Benzinga
Recap: Celcuity Q4 Earnings
March 23, 2022
Celcuity (NASDAQ:CELC) reported its Q4 earnings results on Wednesday, March 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Celcuity...
Via
Benzinga
Earnings Scheduled For March 23, 2022
March 23, 2022
Companies Reporting Before The Bell • AYRO (NASDAQ:AYRO) is expected to report earnings for its fourth quarter. • First Trust NASDAQ Clean Edge Smart Grid...
Via
Benzinga
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
March 20, 2022
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
March 17, 2022
Thursday saw 34 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: SecureWorks (NASDAQ:SCWX) was the largest company by market cap to...
Via
Benzinga
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call
March 16, 2022
MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...
From
Celcuity Inc.
Via
AccessWire
Celcuity to Participate in the Cowen 42nd Annual Health Care Conference
March 02, 2022
MINNEAPOLIS, MN / ACCESSWIRE / March 2, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...
From
Celcuity Inc.
Via
AccessWire
FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity
January 18, 2022
The FDA has granted Fast Track designation to Antares Pharma Inc's (NASDAQ: ATRS) for ATRS-1902 for adrenal crisis rescue. The development program...
Via
Benzinga
Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update
January 18, 2022
- FDA's Fast Track Designation for the pan-PI3K/mTOR inhibitor highlights potential to address the urgent need for new treatment options for breast cancer patients - On track to finalize Phase 3...
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 22, 2021
Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV...
Via
Benzinga
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium
December 10, 2021
78% ORR in 3rd line patients and 63% ORR overall in patients treated with three weeks on/one week off gedatolisib dosing schedule (Arm D) MINNEAPOLIS, MN / ACCESSWIRE / December 10, 2021 / Celcuity...
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium
December 02, 2021
MINNEAPOLIS, MN / ACCESSWIRE / December 2, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...
From
Celcuity Inc.
Via
AccessWire
Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development
November 29, 2021
MINNEAPOLIS, MN / ACCESSWIRE / November 29, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...
From
Celcuity Inc.
Via
AccessWire
Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial
November 15, 2021
MINNEAPOLIS, MN / ACCESSWIRE / November 15, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences
November 09, 2021
MINNEAPOLIS, MN / ACCESSWIRE / November 9, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...
From
Celcuity Inc.
Via
AccessWire
Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 08, 2021
- On track to obtain FDA feedback and initiate a Phase 3 study for gedatolisib during the first half of 2022 - Will present updated Phase 1b data during a Spotlight Poster Discussion Session at the...
From
Celcuity Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call
October 29, 2021
MINNEAPOLIS, MN / ACCESSWIRE / October 29, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating...
From
Celcuity Inc.
Via
AccessWire
The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio
October 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In...
Via
Benzinga
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases
October 18, 2021
From
Celcuity Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2021
September 07, 2021
Upgrades BMO Capital upgraded the previous rating for BRP Inc (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 8, 2021
October 08, 2021
Upgrades UBS upgraded the previous rating for Northern Trust Corp (NASDAQ:
Via
Benzinga
Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 09, 2021
- Raised approximately $56.3 million of gross proceeds from a follow-on public offering of common stock in early July to provide funding for clinical development activities - After follow-on offering,...
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference
August 05, 2021
MINNEAPOLIS, MN / ACCESSWIRE / August 5, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating...
From
Celcuity Inc.
Via
AccessWire
Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast
August 02, 2021
MINNEAPOLIS, MN / ACCESSWIRE / August 2, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for...
From
Celcuity Inc.
Via
AccessWire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.